Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | CTNNB1 | P35222 | 8/20 | 0.60 |
| ▸ | WNT3A | P56704 | 8/20 | 0.60 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.59 |
| ▸ | FEN1 | P39748 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29541385 | 1.00 | KMT2A (0.62) | KMT2AMEN1CTNNB1WNT3AERCC5 | |
| SCHEMBL15979740 | 0.92 | CTNNB1 (0.68) | KMT2AMEN1CTNNB1WNT3AERCC5 | |
| SCHEMBL30089517 | 0.92 | CTNNB1 (0.68) | KMT2AMEN1CTNNB1WNT3AERCC5 | |
| SCHEMBL29634736 | 0.90 | ERCC5 (0.58) | KMT2AMEN1CTNNB1WNT3AERCC5 | |
| SCHEMBL7914414 | 0.90 | ERCC5 (0.58) | KMT2AMEN1CTNNB1WNT3AERCC5 | |
| SCHEMBL15979719 | 0.86 | NR4A2 (0.59) | KMT2ACTNNB1WNT3AERCC5FEN1 | |
| SCHEMBL7475817 | 0.85 | KMT2A (0.54) | KMT2AMEN1CTNNB1WNT3AERCC5 | |
| SCHEMBL3027929 | 0.84 | CTNNB1 (0.60) | KMT2AMEN1CTNNB1WNT3AERCC5 | |
| O-Xylene SCHEMBL8120631 | 0.83 | KMT2A (0.66) | KMT2AMEN1CTNNB1WNT3AHTT | |
| SCHEMBL14053729 | 0.82 | KMT2A (0.51) | KMT2AMEN1CTNNB1WNT3AERCC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4652291-A1 | SCARLESS TEMPLATE-FREE ENZYMATIC SYNTHESIS OF POLYNUCLEOTIDES | DNA Script (FR) | 2025-11-26 | — | — | EP | disclosed |
| WO-2024153642-A1 | SCARLESS TEMPLATE-FREE ENZYMATIC SYNTHESIS OF POLYNUCLEOTIDES | DNA SCRIPT (FR) | 2024-07-25 | — | — | WO | disclosed |
| CN-107129716-B | Putty composition and the repairing/coating process for using the putty composition | 关西涂料株式会社 | 2019-08-13 | — | — | CN | disclosed |
| CN-107129716-A | Putty composition and the repairing/coating process using the putty composition | 关西涂料株式会社 | 2017-09-05 | — | — | CN | disclosed |
| US-8143425-B2 | Heterocyclic aromatic compounds useful as growth hormone secretagogues | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| EP-1799208-A2 | HETEROCYCLIC AROMATIC COMPOUNDS USEFUL AS GROWTH HORMONE SECRETAGOGUES | Brystol-Myers Squibb Company (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006044359-A2 | HETEROCYCLIC AROMATIC COMPOUNDS USEFUL AS GROWTH HORMONE SECRETAGOGUES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060079562-A1 | Heterocyclic aromatic compounds useful as growth hormone secretagogues | BRISTOL-MYERS SQUIBB COMPANY | 2006-04-13 | — | — | US | disclosed |
| US-6911444-B2 | Non-steroidal IL-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors | JANSSEN PHARMACEUTICS N.V. (BE) | 2005-06-28 | — | — | US | disclosed |
| CN-1188410-C | Nonsteroid IL-5 inhibitor, its preparation method and medical composition containing the inhibitor | JANSSEN PHARMACEUTICA NV (BE) | 2005-02-09 | — | — | CN | disclosed |
| US-20030114453-A1 | Non-steroidal IL-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-06-19 | — | — | US | disclosed |
| CN-1368972-A | Non-steroidal IL-5 inhibitors, process for their preparation and pharmaceutical compositions containing them | JANSSEN PHARMACEUTICA NV (BE) | 2002-09-11 | — | — | CN | disclosed |
| US-6211234-B1 | BENZONITRILE COMPOUNDS WITH ETHER AND SULFIDE GROUPS WITH CARBOXY ACID | RHONE-POULENC RORER LIMITED (GB) | 2001-04-03 | — | — | US | disclosed |
| EP-0728128-B1 | SUBSTITUTED PHENYL COMPOUNDS | RHONE POULENC RORER LTD (GB) | 1998-09-16 | — | — | EP | disclosed |
| EP-0728128-A1 | SUBSTITUTED PHENYL COMPOUNDS | RHONE-POULENC RORER LIMITED (GB) | 1996-08-28 | — | — | EP | disclosed |
| WO-1995013262-A1 | SUBSTITUTED PHENYL COMPOUNDS | RHONE-POULENC RORER LIMITED (GB) | 1995-05-18 | — | — | WO | disclosed |
| EP-0206741-B1 | LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079562-A1 | Heterocyclic aromatic compounds useful as growth hormone secretagogues | GHRHR, GHSR, NPY1R | KMT2A 2520/4885MEN1 1250/4885CTNNB1 2997/4885 |
| US-20030114453-A1 | Non-steroidal IL-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors | IL5, IL15, IL15RA | KMT2A 3703/4885MEN1 3774/4885CTNNB1 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.